Digital JPM2026: Broadening AI drug discovery to include the lab, wi... Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.
Digital JPM2026: AI diagnostics and translational research, with And... On the sidelines of JPM2026, pharmaphorum spoke with Andrew Beck, co-founder and CEO at PathAI, about AI diagnostics in pathology.
Digital An AI supercomputer and discovering next-gen brain disorder ... Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.
Digital AI for the planet, AI for life sciences – with Patrick Leung Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials.
Digital On the future of AI in life sciences, with women at the helm Dive into a conversation on women in AI, with: Kate Eversole, Pharma Brands; Celine Parmentier, Real Chemistry; and Emma Slade, Tangram Therapeutics.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
News Lilly unveils employer scheme for weight-loss drug Zepbound Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.